The role of interleukin-6 in gynaecological malignancies

被引：39

作者：

Coward, Jermaine I. G. ^{[1
]}

Kulbe, Hagen ^{[2
]}

机构：

[1] Mater Hosp, Mater Med Res Inst, Canc Therapeut Grp, Brisbane, Qld 4101, Australia

[2] Barts Canc Inst, Ctr Canc & Inflammat, London EC1 6BQ, England

来源：

CYTOKINE & GROWTH FACTOR REVIEWS | 2012年 / 23卷 / 06期

关键词：

Interleukin-6; Tumour microenvironment; Epithelial ovarian cancer; Endometrial cancer; Cervical cancer; NECROSIS-FACTOR-ALPHA; ACTIVATED SIGNAL TRANSDUCER; OVARIAN-CANCER CELLS; PHASE-II TRIAL; ENDOMETRIAL CANCER; GROWTH-FACTOR; SERUM-LEVELS; EPITHELIAL OVARIAN; CERVICAL-CANCER; GENE-EXPRESSION;

D O I：

10.1016/j.cytogfr.2012.08.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

There are many parallels between gynaecological cancers in relation to cytokine networks within their respective tumour microenvironments and evidence to support interleukin-6 (IL-6) being an appropriate therapeutic target in these diseases. This article provides an overview on IL-6 biology including updates on novel discoveries in IL-6 signalling and then focuses on the role of IL-6 in processes such as cell proliferation, migration, angiogenesis, evasion of tumour immunity and chemoresistance and presents data relating to the abrogation of these processes with anti-IL-6 targeted therapy in prechnical and clinical studies. The overall aim will be to highlight the necessity for further translational studies concentrating on combinations of anti-IL-6/IL-6R therapies with other novel targets in an attempt to significantly improve overall survival in patients with gynaecological cancers. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：333 / 342

页数：10

共 127 条

[1]

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].

Aghajanian, Carol ;

Blank, Stephanie V. ;

Goff, Barbara A. ;

Judson, Patricia L. ;

Teneriello, Michael G. ;

Husain, Amreen ;

Sovak, Mika A. ;

Yi, Jing ;

Nycum, Lawrence R. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045

[2]

Phase II Trial of Bevacizumab in Recurrent or Persistent Endometrial Cancer: A Gynecologic Oncology Group Study [J].

Aghajanian, Carol ;

Sill, Michael W. ;

Darcy, Kathleen M. ;

Greer, Benjamin ;

McMeekin, D. Scott ;

Rose, Peter G. ;

Rotmensch, Jacob ;

Barnes, Mack N. ;

Hanjani, Parviz ;

Leslie, Kimberly K. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) :2259-2265

[3]

The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages [J].

Allavena, Paola ;

Sica, Antonio ;

Solinas, Graziella ;

Porta, Chiara ;

Mantovani, Alberto .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2008, 66 (01) :1-9

[4]

IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer [J].

Anglesio, Michael S. ;

George, Joshy ;

Kulbe, Hagen ;

Friedlander, Michael ;

Rischin, Danny ;

Lemech, Charlotte ;

Power, Jeremy ;

Coward, Jermaine ;

Cowin, Prue A. ;

House, Colin M. ;

Chakravarty, Probir ;

Gorringe, Kylie L. ;

Campbell, Ian G. ;

Okamoto, Aikou ;

Birrer, Michael J. ;

Huntsman, David G. ;

de Fazio, Anna ;

Kalloger, Steve E. ;

Balkwill, Frances ;

Gilks, C. Blake ;

Bowtell, David D. .

CLINICAL CANCER RESEARCH, 2011, 17 (08) :2538-2548

[5]

Dimerization and activation of the common transducing chain (gp130) of the cytokines of the IL-6 family by mAb [J].

Autissier, P ;

De Vos, J ;

Liautard, J ;

Tupitsyn, N ;

Jacquet, C ;

Chavdia, N ;

Klein, B ;

Brochier, J ;

Gaillard, JP .

INTERNATIONAL IMMUNOLOGY, 1998, 10 (12) :1881-1889

[6]

IL-6 and Ovarian Cancer-Response [J].

Balkwill, Frances R. ;

Coward, Jermaine ;

Kulbe, Hagen ;

Milagre, Carla ;

Gopinathan, Ganga ;

McNeish, Iain A. .

CLINICAL CANCER RESEARCH, 2011, 17 (24) :7838-7838

[7]

Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[8]

High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer [J].

Bellone, S ;

Watts, K ;

Cane, S ;

Palmieri, M ;

Cannon, MJ ;

Burnett, A ;

Roman, JJ ;

Pecorelli, S ;

Santin, AD .

GYNECOLOGIC ONCOLOGY, 2005, 98 (01) :92-98

[9]

SERUM INTERLEUKIN-6 LEVELS CORRELATE WITH DISEASE STATUS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER [J].

BEREK, JS ;

CHUNG, C ;

KALDI, K ;

WATSON, JM ;

KNOX, RM ;

MARTINEZMAZA, O .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (04) :1038-1043

[10]

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].

Bettelli, E ;

Carrier, YJ ;

Gao, WD ;

Korn, T ;

Strom, TB ;

Oukka, M ;

Weiner, HL ;

Kuchroo, VK .

NATURE, 2006, 441 (7090) :235-238

← 1 2 3 4 5 6 7 8 9 10 →